Senti Biosciences (SNTI) to Release Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI) is anticipated to post its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $1.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Senti Biosciences Price Performance

NASDAQ SNTI opened at $1.01 on Thursday. Senti Biosciences has a one year low of $0.80 and a one year high of $5.10. The stock’s 50-day moving average is $0.99 and its 200-day moving average is $1.43. The firm has a market cap of $26.55 million, a P/E ratio of -0.30 and a beta of 2.12.

Hedge Funds Weigh In On Senti Biosciences

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its position in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares during the last quarter. Armistice Capital LLC acquired a new position in shares of Senti Biosciences during the 2nd quarter worth approximately $1,883,000. Citadel Advisors LLC bought a new stake in Senti Biosciences in the 3rd quarter valued at $117,000. Jane Street Group LLC bought a new stake in Senti Biosciences in the 4th quarter valued at $40,000. Finally, Virtu Financial LLC acquired a new stake in Senti Biosciences during the 4th quarter valued at $46,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. Chardan Capital upped their target price on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. Finally, Leerink Partners started coverage on Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Senti Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.